CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.85
+6.03%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.46x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.17x
- Price / sales
- 2.59x
- Price / cash flow
- -0.54x
Enterprise value
- Enterprise value
- $64.4M
- EV / sales
- 1.26x
- EV / EBITDA
- -0.43x
- EV / EBIT
- -0.41x
- Market cap
- $132.0M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026